{
    "nctId": "NCT00301899",
    "briefTitle": "Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab",
    "officialTitle": "A Phase II Study to Evaluate the Efficacy and Safety Using Combined Monoclonal Antibodies, Trastuzumab and Pertuzumab in Subjects With Her-2 Overexpressed Locally Advanced and Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "N/A",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 37,
    "primaryOutcomeMeasure": "Safety",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed invasive breast cancer of 1 of the following stages:\n\n  * Metastatic disease (stage IV)\n  * Inoperable locally advanced disease\n\n    * Disease progression after prior neoadjuvant chemotherapy required\n* Disease progression on or after trastuzumab (Herceptin\u00ae) based-therapy\n\n  * Received 1-3 prior trastuzumab-based regimens\n* HER2/neu-positive tumor, defined as 3+ by fluorescent in situ hybridization\n* Measurable disease, defined as at least 1 lesion that can be measured in at least one dimension\n* No clinical signs or symptoms of brain and/or leptomeningeal metastases confirmed by CT scan or MRI\n\n  * Brain and/or leptomeningeal metastases allowed if patient has stable lesions after standard treatment (surgery or radiotherapy), is asymptomatic on neurological exam, and is not receiving corticosteroid therapy to control symptoms\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\n* ECOG performance status 0-1\n* Male or female\n* Menopausal status not specified\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* Absolute neutrophil count \u2265 1,500/mm\\^3\n* Platelet count \u2265 75,000/mm\\^3\n* Creatinine \u2264 1.5 times upper limit of normal (ULN)\n* Bilirubin \u2264 1.5 times ULN\n* Alkaline phosphatase \\< 5 times ULN\n* AST and ALT \u2264 2.5 times ULN (5 times ULN if liver metastases are present)\n* LVEF above lower limit of normal by echocardiogram or MRI\n* No clinical signs or symptoms of heart failure\n* No uncontrolled hypertension (i.e., blood pressure \u2265 180/100 mm Hg)\n* No significant valvular disease (i.e., aortic or mitral regurgitation of 3 or 4+/4+ severity or stenosis of either valve)\n* No history of uncontrolled cardiac arrhythmia\n* No symptomatic or asymptomatic myocardial infarction\n* No angina pectoris requiring medication\n* No other documented significant cardiac event\n* No poorly controlled diabetes mellitus (i.e., fasting blood sugar \u2265 200 mg/dL)\n* No history of hypersensitivity reaction to trastuzumab\n* No AIDS\n* No nonmalignant condition requiring \u2265 20 mg of prednisone (or equivalent)\n* No other malignancy within the past 5 years except carcinoma in situ of the cervix or nonmelanoma skin cancer\n* No ongoing liver disease, including viral or other hepatitis, alcohol abuse, or cirrhosis\n* No other serious medical illness\n* No medical or psychiatric condition that would preclude study participation\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from prior therapy\n* More than 3 weeks since prior investigational anticancer agents\n* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C), major surgery, or immunotherapy\n* More than 4 weeks since prior radiotherapy except short-course palliative radiotherapy for bone pain\n* More than 2 weeks since prior and no concurrent oral hormonal therapy\n* More than 4 weeks since prior fulvestrant\n* No prior doxorubicin hydrochloride or doxorubicin HCl liposome at a cumulative dose of \\> 360 mg/m\\^2\n* No prior mitoxantrone hydrochloride at a cumulative dose of \\> 120 mg/m\\^2\n* No prior epirubicin hydrochloride at a cumulative dose of \\> 600 mg/m\\^2\n* No prior idarubicin at a cumulative dose of \\> 90 mg/m\\^2\n* No concurrent radiation therapy, including for symptomatic bone metastases",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}